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Introduction
Antibodies have attracted increasing interest as therapeutics due to their 
unique
biophysical characteristics, such as good solubility, stability, high
specificity, and
prolonged plasma concentration.
bispecific antibodies have been developed as a powerful approach to
cancer immunotherapy 
by engaging immune cells to target cancer cells.
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Bispecific antibodies have  two different antigen-binding sites:  
1)recognizes tumor cells 
2)recognizes immune cells, usually T cells or natural killer(NK) cells.
Nb Derived from natural camel heavy-chain only antibodies
single-domain antibodies lack the first constant (CH1) domain and light
chain and are consequently referred to as nanobodies or VHHs
Nanobodies are small sized 
more stable than c ScFvs or BiTEs )bispecific t-cell engager)
a good scaffold for constructing bispecific antibodies
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• S-fab was developed -can bind to diverse epitope-be synthesized in 
prokaryotic expression systems.
• S-Fab has potent in vitro cytotoxicity
• suppresses cancer progression in in vivo studies
• have a short plasma half-life
To improve the in vivo half-life of proteins:
1) conjugation to polyethyleneglycol (PEG; PEGylation)
2)  N-(2-hydroxypropyl) methacryl-amide (HPMA) copolymers
3)proteins (such as albumin)
4) polyglutamic acid and PASylation
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In this study, we explored thiol site-specific PEGylation
to improve the half-life (t1/2) of the CEA-S-Fab bispecific antibody
, which is an antiCEA/CD3 bispecific S-Fab
A functionalized 20 kDa linear PEG was conjugated to S-Fab.
To retain the properties of CEA-S-Fab, the site for conjugation was 
designed to be distant to both CEA- and CD3-binding sites.
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8Material and methods
The 20 kDa linear methoxy PEG maleimide (MAL-PEG-OMe; 
Lot A3115)
Human colon adenocarcinoma cell line LS174T and human 
breast cancer cell line SKOV3
(NOD–SCID) mice (18–22 g)
Adult male Sprague Dawley (SD) rats(250–300 g) that were 
used for PK analysis
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Methods
1)S-Fab design and protein purification
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To produce S-Fab, two plasmids encoding the VH-CH1-VHH and VL-CL
polypeptides were co-transformed into BL21 (DE3, codon plus) competent 
cells with the appropriate antibiotics.
When the absorbance (OD600) of the cell culture reached 0.8
0.2 mM isopropyl-β-d-thiogalactoside (IPTG)was added to induce protein 
expression.
Cells were cultured at
16°C for another 40 h before harvesting.
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periplasmic extraction was performed
by re-suspending the cell pellets  in a pre-cooled sucrose solution (20 mM
Tris-HCl, pH 7.5; 25% [w/v]sucrose; 1 mM EDTA).
After incubation on ice, the
suspension was centrifuged and the supernatant fraction was collected as the 
sucrose fraction.
The pellet was re-suspended in a chilled periplasmic solution
(5 mM MgCl2) and centrifuged .
supernatant was gathered as the periplasmic fraction.
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The S-Fab  was purified from the combined sucrose and periplasmic 
fractions by a two-step :
1) by immobilized Ni-NTA affinity 
chromatography 
2) by an IgG-CH1affinity matrix 
Gel filtration analysis was performed using a Bio-Rad FPLP system 
analysis under reducing conditions.
The resulting fractions were visualized by Coomassie blue staining.
Protein mark-ers (Lot MWGF200; Sigma-Aldrich Co.) were loaded as
standard controls for gel filtration analysis.
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2)Conjugation of S-Fab to PEG
• S-fab in 5ml pbs &1 mM tris 2-carboxy ethyl phosphine were mixed and 
ancubated to obtain reduced s-fab fragment
• To explore the optimal molar ratio of MAL-PEG-Ome and S-Fab in the 
PEGylation
• a series of reactions with the molar equivalents of PEG:S-Fab of
0:1, 10:1, 20:1, 40:1, and 60:1. 
MAL-PE - OMe was dis-solved in sterile water to obtain a working 
concentration of 20 mg/mL (1 mM).
• PEGylationof S-Fab was carried out by mixing MAL-PEG- OMe (at the 
working concentration) with reduced S-Fab and shaking at 22°C for 2 h.
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• Result           samples         12%reduced             SDS-PAGE
or non reduced
• western blot transfer polyvinylidene fluride
bloking (skimmed milk)            membrane were incubated with 
antiflag HRP(1:2000 heavy chain) and anti-His IgG(1:3000 light-
chain) in5%skim milk              after  washing with tris-buffered
saline &Tween 20 buffer              secondary Ab (HRP-conjougate
IgG1:13000)Incubated with light-chain          membrane were 
developed pierce’s west pico chemiluminescence
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3)Purification of PEG-S-Fab using               4)Human CD3 T-cell isolation
fast protein liquid chromatography
15
5)Flow cytometric analysis
1)Detect CEA            cell line LS174T & SKOV3 centrifugation 
washing ice-cold PBS+0.2% BSA               1×106 LS174T & SKOV3or 
5×105 TCELL                         S-Fab & PEG_sfab incubated on ice for 1h
washing twice with ice-cold PBS +BSA         . Anti-CD3 fluoresceine
isothiocyanate (OKT3) as +control forCD3+antigen-binding analysis .
Goat antihuman IgG (H +L)-AlexaFluor 488 antibody added .      cells 
were incubated on ice for 1 h          After washing the cells twice,.           Flow 
cytometric
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6)Immunofluorescence assay
1)LS174T & SKOV3 were plated 30 mm confocal glass bottom dishes
2) Washed with cold PBS three times
3)Fixed cells were incubated with S-fab or peg-s fab + IgG (H+L)AlexaFluor488
antibody for 2 h at 4°C.
4) Cell nuclei were counterstained with 4′,6-diamidino-2-phenyl indole (DAPI). 
5) washing with PBS, 
6)the sampleswere examined under an scan-ning confocal microscope
7) analyzed using the Olympus FV31S-SW_V2.1 software.
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7)In vitro cytotoxicity
1) LS174 & SKOV3 target cells
2) CD3+ T cell without prior stimulation                      effector cells
3) Cytotoxicity assay            96-well microplate -triplate-seeding 5000 target cell 
in 100ML media
4) 6 h incubation an equal volume of CD3+ Tcell add  to each well
an E:T ratio of 10:1
5)add a series of concentrations (0.033,0.1, 0.33, 1, 3.3, 10, 33, and 100 
nM) of S-Fab or PEG-S-Fab 
6) After a 72 h incubation, the cell viability was evaluated 
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8)PK assay to determine the in vivo half-life
1) Specific pathogen free male SD rats (250–300 g) were used
for the PK assay.
2). S-Fab , PEG-S-Fab, or a volume equivalent of the vehicle solutionPBS
was administered through the caudal vein.
3) 0, 0.5, 1, 2, 4,8, 16, 24, 36, 48, 72, 96, and 144 h after administration
.        Sample blood         orbital vein         using capillary
4)Blood sample         centrifugation            stored at -80
5) S-Fab & PEG-S-Fab in the plasma samples were quanti-
fied using ELISA.
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6)100 μL aliquot of 6D6 (mouse antihuman IgG Fab antibody; 1.0 μg/mL in 
PBS) was used to coat each well of a 96-well ELISA microplate for 2 h at 
37°C.
7) The wells were blocked with blocking buffer(PBST containing 1% BSA) 
8) Samples and standards (100, 80,50, 40, 30, 20, 10, 5, 1, and 0.1 μg/mL) in 
blocking buffer           (S-Fab)/PBS 1:10          important,to avoid matrix 
effects in the assay
9) 1:3 dilution plasma 
10)Sample added in triplicate and  incubated
11) each well           washed with PBST            added secondary 
Ab(mousemonoclonal antiflagM2-peroxidase [HRP] antibody at 1:500 
dilutions)per well
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12) Five time washed          100 μL tetramethylbenzidine substrate solution 
was add to each well
13)Incubation
14) 100 μL of 2 M H2SO4 Was added to stop the reaction
15) The absorbance was detected at 450 nm using a Tecan ELISA 
microplate reader.
16)The serum elimination t1/2 and clearance were calculated
with 3P97 PK software
.
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9)Plasma stability analysis
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10)In vivo tumor growth inhibition
1)using NOD-SCID mice engrafed subcutane ously with LS174 cell
2)Cells harvested and washed once with PBS and mixed with human
PBMCs that were freshly isolated from healthy donors.
3) Mixtures of LS174T cells and human PBMCs
were subcutaneously injected into the right flank of NOD–SCID mice
4) One hour after engraftment, S-Fab & PEG-S-Fab or the vehicle control 
(PBS) were injected intraperitoneally.
5) The tumor volume was measured with calipers in two perpendicular 
dimensions 
6) All data were expressed as the mean ± SEM for each group,
and differences between groups were determined by a two-
way analysis of variance using the GraphPad Prism 5 soft-
ware
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Result
1)Bispecific S-fab construction and purification
• S-fab was constructed with the following specification
• Peptid(CGGGGC) added to 
C-terminal of anti-CD3 CL-VL
• Cloned into PET26b & PET21a 
With signal peptide for pelB
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• C)
• Ligh chain 
25KD
• Heavy chain
40KD
(under reducing 
condition 2-
mecapto ethanol)
A major binding 
130KD observed
(under 
nonreducing)=
Dimerzation s-
fab
d)Gel filtration analysis 
Intact s-fab Ab 130KD
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2)Conjugation 
of s-fab to PEG
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3)Purification 
of PEG-S-Fab 
using fast
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4)PEG-S-Fab can bind the tumor antigen CEA and CD3 T cells
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6)PEGylation prolongs the in vivo half-life of s-fab
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7)PEG-S-fab induces more potent in vivo antitumor activity
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Discussion
• In this study, we demonstrated that the site-specific PEGy-lation can 
improve the therapeutic profiles of the bispecific
• S-Fab showed potent antitumor activities in vitro and in vivo
• As a Fab format, S-Fab offers advantages over full-length antibodies, 
including better penetration into tumor tissues and simple production of 
the antibody using inexpensive prokaryotic expression systems.
• the short in vivo half-life of S-Fab limits its potential as a therapeutic 
agent.
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In the case of antibody fragments, PEGylation has been
shown to lengthen their circulating half-life, 
enhance their proteolytic resistance of therapeutic proteins, and reduce
their immunogenicity.
PEGylation potentially decrease enzymatic proteins or the binding affinities 
of Fabs.
Flow cytometry analysis showed that PEGylation had a slight effect on the 
binding of S-Fab to tumor cells and T cells and slightly
reduced the in vitro cytotoxicity
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PEGylation increased the circulation t 1/2 of S-Fab by 12-fold
in vivo 
. enhancement of the in vivo half was due to the
hydrodynamic radius and enhanced molecular size of the
PEGylated conjugate
leading to reduced renal clearance and increased resistance of the PEGylated 
conjugate to proteolysis.
In mouse models, PEG-S-Fab showed more potent antitumor activity than S-
Fab
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Conclusion
this study supports the use of PEGylation to extend the circulating 
half-life of the bispecific antibody
S-Fab and enhance its therapeutic potential in the clinic.
This strategy can be potentially applied to a broad range of
immunotherapies.
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